Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 9/30/2015 | 6/30/2015 | 3/31/2015 | |
|---|---|---|---|---|
| Market Cap | $422 | $480 | $3,069 | $5,354 |
| - Cash | $83 | $21 | $21 | $223 |
| + Debt | $5,295 | $5,222 | $5,268 | $5,354 |
| Enterprise Value | $5,634 | $5,682 | $8,316 | $10,485 |
| Revenue | $1,289 | $1,562 | $1,342 | $1,068 |
| % Growth | -17.5% | 16.4% | 25.7% | – |
| Gross Profit | $776 | $1,065 | $807 | $517 |
| % Margin | 60.2% | 68.2% | 60.2% | 48.4% |
| EBITDA | -$313 | $79 | -$222 | -$1,207 |
| % Margin | -24.3% | 5.1% | -16.5% | -113% |
| Net Income | -$581 | -$238 | -$546 | -$1,678 |
| % Margin | -45.1% | -15.2% | -40.7% | -157.2% |
| EPS Diluted | -0.021 | -0.01 | -0.02 | -0.06 |
| % Growth | -114% | 50% | 66.7% | – |
| Operating Cash Flow | $77 | $132 | -$26 | -$1,461 |
| Capital Expenditures | $0 | $0 | $0 | -$4 |
| Free Cash Flow | $77 | $132 | -$22 | -$1,465 |